Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Short term Debt (2016 - 2025)

Sanofi's Short term Debt history spans 10 years, with the latest figure at $4.5 billion for Q4 2024.

  • For Q4 2024, Short term Debt rose 104.41% year-over-year to $4.5 billion; the TTM value through Dec 2024 reached $4.5 billion, up 104.41%, while the annual FY2024 figure was $4.6 billion, 105.94% up from the prior year.
  • Short term Debt for Q4 2024 was $4.5 billion at Sanofi, up from $2.2 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $4.5 billion in Q4 2024 and bottomed at $2.2 billion in Q4 2023.
  • The 5-year median for Short term Debt is $3.6 billion (2021), against an average of $3.6 billion.
  • The largest annual shift saw Short term Debt tumbled 48.33% in 2023 before it skyrocketed 104.41% in 2024.
  • A 5-year view of Short term Debt shows it stood at $3.3 billion in 2020, then increased by 10.37% to $3.6 billion in 2021, then grew by 16.95% to $4.3 billion in 2022, then plummeted by 48.33% to $2.2 billion in 2023, then skyrocketed by 104.41% to $4.5 billion in 2024.
  • Per Business Quant, the three most recent readings for SNY's Short term Debt are $4.5 billion (Q4 2024), $2.2 billion (Q4 2023), and $4.3 billion (Q4 2022).